logo
Share SHARE
FONT-SIZE Plus   Neg

Tranzyme Pharma Says That First Phase 3 Pivotal Trial Of Ulimorelin Failed

Late-stage biopharmaceutical company Tranzyme Pharma (TZYM), on Monday, along with specialty pharmaceutical company Norgine B.V., announced top-line results of the primary analysis of ULISES 007, the first of two Phase 3 pivotal trials evaluating ulimorelin.

The company stated that the trial failed to meet its primary and secondary efficacy endpoints.

Tranzyme further stated that the results of ULISES 007 showed that ulimorelin, at both 160 and 480 micrograms/kg doses, was not statistically different from placebo for the primary endpoint.

"These results are surprising and disappointing. While we are still planning to analyze the data from the second phase 3 trial ULISES 008, which we expect by the end of the second quarter, we are stopping all other NDA activities for ulimorelin," said Vipin K. Garg, Ph.D., President and Chief Executive Officer, Tranzyme Pharma.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Mastercard Inc. said that after April 2018, customers will no longer be required to sign for any purchases they made on the card at retail. The company added that the change, which will apply to both credit and debit cards, will not have any negative impact on safety. Procter & Gamble Company (PG) Friday reported a profit for the first quarter fiscal year 2018 that grew 5 percent from last year, while quarterly net sales increased one percent. Adjusted earnings per share topped analysts' expectations. The company maintained its expectation for fiscal year 2018. Conglomerate General Electric Co. reported Friday weak earnings in its third quarter, despite increased revenues and orders. Adjusted earnings were sharply lower than market estimates, while top line beat their view. In pre-market activity, GE shares were losing around 5 percent.
comments powered by Disqus
Follow RTT